Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Bookmark and Share
Published: 30 May 2015
Views: 2435
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

Dr Usmani talks to ecancertv at ASCO 2015 about a phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.

Read the news article and watch the press conference for more.